Recombinant Human BDNF Biotinylated Protein, CF

Catalog #: BT11166 Datasheet / COA / SDS

Biotinylated

Catalog #	Availability	Size / Price	Qty
BT11166-025

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human BDNF Biotinylated Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human TrkB Fc Chimera (Catalog # 688-TK) is immobilized at 0.5 μg/mL (100 μL/well), Biotinylated Recombinant Human BDNF (Catalog # BT11166) binds with an ED₅₀ of 1.00-10.0 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human BDNF protein
His129-Arg247

Accession #

P23560.1

N-terminal Sequence
Analysis

His129

Structure / Form

Biotinylated via amines

Predicted Molecular Mass

13.5 kDa

SDS-PAGE

11-16 kDa, under reducing conditions.

Product Datasheets

BT11166

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

BT11166

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

Measured by its binding ability in a functional ELISA. When Recombinant Human TrkB Fc Chimera (688-TK) is immobilized at 0.5 μg/mL (100 μL/well), Biotinylated Recombinant Human BDNF Protein (Catalog # BT11166) binds with an ED₅₀ of 1.00-10.0 ng/mL

Reconstitution Calculator

Background: BDNF

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors that are required for the differentiation and survival of specific neuronal subpopulations in both the central as well as the peripheral nervous system. The neurotrophin family is comprised of at least four proteins including BDNF, nerve growth factor (NGF), neurotrophin-3 (NT3), and NT4/5. Human BDNF is initially expressed as a proprotein, which is then cleaved to yield a mature protein. Mature BDNF is a non-covalently linked homodimer, with each monomer containing antiparallel beta -strands and a characteristic cystine knot motif. Within the mature domain, human BDNF shares the identical amino acid sequence with mature mouse and rat BDNF. BDNF is strongly expressed in various regions of the brain, including the hippocampus and cerebellum, and weaker expression has been detected in the thymus, liver, spleen, heart, and lung. BDNF participates in axonal growth and pathfinding and in the modulation of dendritic growth and morphology and in later stages of development regulates synaptic transmission and plasticity and acts as a central modulator of pain. BDNF binds with high affinity and specifically activates the TrkB tyrosine kinase receptor. BDNF signaling via TrkB is essential for adult synaptic plasticity and the formation of memories. The BDNF signaling pathway utilizes both AKT and ERK pathways to exert its pleiotrophic effects in the central nervous system. Decreased expression of BDNF is seen in many neurological diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and autism. Further, BDNF is proposed as a biomarker for psychiatric disorders such as bipolar disease and depression and has been implicated in posttraumatic stress disorder, phobia, and panic disorder. A single amino acid substitution, Val66Met, has been shown to lead to reduced, activity-dependent BDNF secretion and memory impairment.

References